Antibody Design

2 articles

AlphaFold 32×IsoDDEProtein-ligand prediction2× more accurateAntibody-antigen structures2.3× vs AF3, 19.8× vs BoltzNovel binding pocketsfrom sequence aloneBinding affinitybeats FEP at fraction of costIsomorphic Labs · February 2026
Structure Prediction

Isomorphic Labs Unveils IsoDDE Drug Design Engine, Doubling AlphaFold 3's Accuracy in Protein-Ligand Prediction

Isomorphic Labs unveiled IsoDDE, an AI drug design engine that more than doubles AlphaFold 3's accuracy in protein-ligand prediction and identifies novel binding pockets from sequence alone, as the company prepares for its first clinical trials.

·2 min
CHAI DISCOVERY · SERIES B$1.3Bvaluation · $130M raisedChai-2: de novo antibody design100×vs previous methods16%zero-shot hit rate86%drug-like profilesBacked by OpenAI, Thrive, General Catalyst
Antibody Design

Chai Discovery Raises $130M Series B at $1.3B Valuation, Unveils Chai-2 for Zero-Shot Antibody Design

Chai Discovery raised $130M at a $1.3B valuation in December 2025, backed by OpenAI and others, after unveiling Chai-2 with a 100x improvement in zero-shot de novo antibody design and a 16% hit rate.

·2 min

Stay current

Weekly digest of AI drug discovery developments. No noise.